Investigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral Disorder
Primary Purpose
Conduct Disorder, Attention Defict Hyperactivity Disorder
Status
Withdrawn
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Methylphenidate Hydrochloride
Sponsored by
About this trial
This is an interventional other trial for Conduct Disorder focused on measuring Conduct Disorder, Methylphenidate, Disruptive Behavior Disorders
Eligibility Criteria
- INCLUSION CRITERIA
Youth with CD
- 10-17 years of age.
A current diagnosis of CD as determined by the Kiddie-SADS, lifetime version.
- Youth in the CD+comorbid ADHD group will also meet diagnostic criteria for ADHD.
- Youth in the CD without comorbid ADHD group will specifically not meet diagnostic criteria for ADHD.
- Youth with CD shouldmust be na(SqrRoot) ve to psychoactive medication (such as: methylphenidate and amphetamine).
TD youth
- 10-17 years of age.
- No current psychiatric diagnosis, as determined by the Kiddie-SADS, lifetime version.
EXCLUSION CRITERIA
Exclusion criteria for youth with CD (with or without ADHD)
- Comorbid psychotic, major mood, tic, pervasive developmental, and substance abuse disorders.
- Presence of comorbid ADHD is exclusory for the group of patients with CD without ADHD
- History of known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems
- Current weight less than 25kg or over 90kg
Exclusion criteria for all participants (CD with ADHD, CD without ADHD and TD)
- History of serious CNS disease disorder (examples aresuch as: history of seizure, epilepsy, brain tumor, brain hemorrhage, and major CNS infection such as meningitis or encephalitis)
- Previous history of known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems
- Current use of any psychiatric medications and centrally acting medications (such as stimulants, non-stimulant ADHD medications, antidepressants, anxiolytics, antipsychotics and anti-epilepsy medications), and past history of use of psychoactive medication (such as methylphenidate and amphetamine)
- A positive urine pregnancy test
- A Positive urine toxicology, History/current diagnosis of substance abuse/dependence
- Suicidal or homicidal ideation within the past 6 months.
- Wechsler Abbreviated Scale of Intelligence (WASI) (D. Wechsler, 1999) scores <70
- Metal in body (i.e., hearing aid, cardiac pacemaker, bone plates, etc), claustrophobia, or any other condition that would preclude fMRI scanning.
Sites / Locations
Outcomes
Primary Outcome Measures
Patients with CD will show an increase in the amygdala response to fearful expressions such that the difference between BOLD response in patients and TDs is reduced on MPH relative to placebo. ICU score will be a significant covariate of the inc...
Patients with CD will show an increase in reward prediction errors and reward expected value signaling within striatum and ventromedial frontal cortex (vmPFC) such that the difference between BOLD response in patients and TDs is reduced on MPH r...
Patients with CD will show an increase in conflict related signaling within dorsomedial, lateral and parietal cortices such that the difference between BOLD response in patients and TDs is reduced on MPH relative to placebo. Current ADHD sympto...
Secondary Outcome Measures
Symptom profiles measured by the clinical scales listed in the protocol (CBCL, the ICU, Connor s parent report on ADHD symptom) will be significantly related to the BOLD signal changes after methylphenidate administration.
Full Information
NCT ID
NCT02247986
First Posted
September 20, 2014
Last Updated
November 30, 2019
Sponsor
National Institute of Mental Health (NIMH)
1. Study Identification
Unique Protocol Identification Number
NCT02247986
Brief Title
Investigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral Disorder
Official Title
Investigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral Disorder
Study Type
Interventional
2. Study Status
Record Verification Date
May 18, 2015
Overall Recruitment Status
Withdrawn
Study Start Date
September 4, 2014 (undefined)
Primary Completion Date
May 18, 2015 (Actual)
Study Completion Date
May 18, 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Institute of Mental Health (NIMH)
4. Oversight
5. Study Description
Brief Summary
Background:
- Disruptive behavior is a common problem for children and adolescents. It can be treated with some success with stimulant medicine. Researchers want to learn more about how this works.
Objective:
- To learn how the brain changes when taking the medicine methylphenidate for behavior problems.
Eligibility:
Children ages 10 17 with conduct disorder and/or attention deficit disorder.
Healthy volunteers the same age.
Design:
Participants will be screened under a separate protocol.
Participants will have two 3-hour sessions at the clinic. Girls who are menstruating will have a pregnancy test before their scans.
Visit 1: All participants will:
Perform simple tests on a computer.
Fill out a questionnaire along with their parent or guardian.
Have an MRI scan. A magnetic field and radio waves take pictures of the brain. Participants will lie on a table that slides into a metal cylinder. A coil will be placed over their head. They will be in the scanner for 60 minutes, lying still or performing a simple task. They will practice the task before the scan. A computer screen will show them task information during the scan. The scanner makes loud knocking sounds. Participants will get earplugs. Their parent or guardian can stay with them during the scan.
Only participants with behavior disorders will:
Take a pill of the study medicine or placebo.
Be monitored for any side effects.
Visit 2 is a repeat of Visit 1, except participants who got a pill in Visit 1 will get the other pill in Visit 2. For healthy volunteers, the 2 visits are exactly the same.
Detailed Description
OBJECTIVE:
To determine the impact, as indexed by BOLD response, of the administration of dopaminergic agonist (methylphenidate) on the pathophysiology of CD/ODD.
STUDY POPULATION:
Youth with CD/ODD and typically developing (TD) youth.
DESIGN:
The study will involve a 2 session design (methylphenidate [MPH] vs. placebo). Patients with CD/ODD will participate in both sessions. TD youth will be tested for 2 sessions (no medication) to provide an index of typical task response. Activity within regions of interest identified from the TD youth will be used to determine whether MPH reduces differences in BOLD response in CD/ODD relative to TD youth. ICU scores and current ADHD symptomatology will be used as covariates to determine whether these variables moderate the putative increase in BOLD response in target regions in the patients with CD.
OUTCOME MEASURES:
Principle dependent measures will be BOLD responses as measured through core tasks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Conduct Disorder, Attention Defict Hyperactivity Disorder
Keywords
Conduct Disorder, Methylphenidate, Disruptive Behavior Disorders
7. Study Design
Primary Purpose
Other
Study Phase
Phase 1, Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Methylphenidate Hydrochloride
Intervention Description
Bold signal changes by methylphenidate on DBD
Primary Outcome Measure Information:
Title
Patients with CD will show an increase in the amygdala response to fearful expressions such that the difference between BOLD response in patients and TDs is reduced on MPH relative to placebo. ICU score will be a significant covariate of the inc...
Time Frame
2 years from the initiation of the protocol
Title
Patients with CD will show an increase in reward prediction errors and reward expected value signaling within striatum and ventromedial frontal cortex (vmPFC) such that the difference between BOLD response in patients and TDs is reduced on MPH r...
Time Frame
2 years from the initiation of the protocol
Title
Patients with CD will show an increase in conflict related signaling within dorsomedial, lateral and parietal cortices such that the difference between BOLD response in patients and TDs is reduced on MPH relative to placebo. Current ADHD sympto...
Time Frame
2 years from the initiation of the protocol
Secondary Outcome Measure Information:
Title
Symptom profiles measured by the clinical scales listed in the protocol (CBCL, the ICU, Connor s parent report on ADHD symptom) will be significantly related to the BOLD signal changes after methylphenidate administration.
Time Frame
2 years from the initiation of the protocol
10. Eligibility
Sex
All
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
INCLUSION CRITERIA
Youth with CD
10-17 years of age.
A current diagnosis of CD as determined by the Kiddie-SADS, lifetime version.
Youth in the CD+comorbid ADHD group will also meet diagnostic criteria for ADHD.
Youth in the CD without comorbid ADHD group will specifically not meet diagnostic criteria for ADHD.
Youth with CD shouldmust be na(SqrRoot) ve to psychoactive medication (such as: methylphenidate and amphetamine).
TD youth
10-17 years of age.
No current psychiatric diagnosis, as determined by the Kiddie-SADS, lifetime version.
EXCLUSION CRITERIA
Exclusion criteria for youth with CD (with or without ADHD)
Comorbid psychotic, major mood, tic, pervasive developmental, and substance abuse disorders.
Presence of comorbid ADHD is exclusory for the group of patients with CD without ADHD
History of known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems
Current weight less than 25kg or over 90kg
Exclusion criteria for all participants (CD with ADHD, CD without ADHD and TD)
History of serious CNS disease disorder (examples aresuch as: history of seizure, epilepsy, brain tumor, brain hemorrhage, and major CNS infection such as meningitis or encephalitis)
Previous history of known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems
Current use of any psychiatric medications and centrally acting medications (such as stimulants, non-stimulant ADHD medications, antidepressants, anxiolytics, antipsychotics and anti-epilepsy medications), and past history of use of psychoactive medication (such as methylphenidate and amphetamine)
A positive urine pregnancy test
A Positive urine toxicology, History/current diagnosis of substance abuse/dependence
Suicidal or homicidal ideation within the past 6 months.
Wechsler Abbreviated Scale of Intelligence (WASI) (D. Wechsler, 1999) scores <70
Metal in body (i.e., hearing aid, cardiac pacemaker, bone plates, etc), claustrophobia, or any other condition that would preclude fMRI scanning.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James J Blair, Ph.D.
Organizational Affiliation
National Institute of Mental Health (NIMH)
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
18088220
Citation
Waschbusch DA, Carrey NJ, Willoughby MT, King S, Andrade BF. Effects of methylphenidate and behavior modification on the social and academic behavior of children with disruptive behavior disorders: the moderating role of callous/unemotional traits. J Clin Child Adolesc Psychol. 2007 Oct-Dec;36(4):629-44. doi: 10.1080/15374410701662766.
Results Reference
background
PubMed Identifier
11723191
Citation
Blair RJ. Neurocognitive models of aggression, the antisocial personality disorders, and psychopathy. J Neurol Neurosurg Psychiatry. 2001 Dec;71(6):727-31. doi: 10.1136/jnnp.71.6.727.
Results Reference
background
PubMed Identifier
23450288
Citation
White SF, Pope K, Sinclair S, Fowler KA, Brislin SJ, Williams WC, Pine DS, Blair RJ. Disrupted expected value and prediction error signaling in youths with disruptive behavior disorders during a passive avoidance task. Am J Psychiatry. 2013 Mar;170(3):315-23. doi: 10.1176/appi.ajp.2012.12060840.
Results Reference
background
Learn more about this trial
Investigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral Disorder
We'll reach out to this number within 24 hrs